CME Group Inc. · CME · FY2024 Q4 · Calendar Q1 2025

CME 2024: Record Volume, Retail Expansion and New Investment

The analysis supports a constructive but conditional view of CME’s operating trajectory: record activity, retail distribution, product expansion, and technology investment support continued growth, while regulatory execution, competition, fee changes, and capital-allocation questions are material counterweights.

Reported Before market openNASDAQFinancial Services $105.67B market cap
80quality score

Earnings scorecard

Reported versus consensus
Reported EPS — Consensus $2.46
EPS surprise — Reported versus consensus
Reported revenue — Consensus $1.51B
Revenue surprise — Reported versus consensus

Market reaction

prior-close to event-session close
Stock move +3.0% Event window
SPY move -0.3% Same window
Abnormal move +3.3% Stock minus SPY
Volume 1.4× Versus trailing sessions
Subsequent drift +4.4% Up to 20 sessions
CMESPY benchmark

Ask FN2 about CME FY2024 Q4

Transcript, numbers and history already loaded

Free account. Your question opens in FN2 with this report's transcript and numbers attached.

Transcript intelligence

What changed

Compared with the prior-quarter analysis, the current analysis emphasizes a full-year record, a larger 2025 investment program, planned fee and collateral changes, progress toward securities clearing, and additional product initiatives including physical ethanol futures.

Guidance delta

Management maintained its guidance sentiment. The analysis says fee adjustments and a 10-basis-point collateral surcharge are expected to increase pretax earnings by 2%–2.5%; the analysis also identifies $90 million of 2025 capex and $115 million for cloud migration.

Key takeaways

  • Management described 2024 as a record year, with growth across all six asset classes and stronger retail participation through broker partnerships.
  • Product expansion, including micro contracts, commodity products, and potential crypto offerings, is a central growth initiative.
  • Investment is rising through cloud migration, data analytics, and securities-clearing capabilities, while regulatory execution remains important.

Management priorities

  • Expand retail and institutional access through broker partnerships and micro contracts.
  • Advance the securities-clearinghouse application and develop new commodity, crypto, and data products.
  • Continue cloud migration, technology upgrades, international expansion, and client acquisition.

Follow CME with an agent that reads every filing, transcript, and price print. Free to start.

Try FN2 free

Earnings History

Estimate Beat Miss Match
CME REVENUE earnings history estimate and actual scatter chart 9 reported fiscal quarters and 4 future estimate-only quarters. Q4 '23 estimate $1B Q4 '23 actual $1B, beat Q1 '24 estimate $1B Q1 '24 actual $1B, beat Q2 '24 estimate $2B Q2 '24 actual $2B, match Q3 '24 estimate $2B Q3 '24 actual $2B, miss Q2 '25 estimate $2B Q2 '25 actual $2B, beat Q3 '25 estimate $2B Q3 '25 actual $2B, beat Q4 '25 estimate $2B Q4 '25 actual $2B, match Q1 '26 estimate $2B Q1 '26 actual $2B, beat Q2 '26 estimate $2B Q2 '26 actual $2B, beat Q3 '26 estimate $2B Q4 '26 estimate $2B Q1 '27 estimate $2B Q2 '27 estimate $2B
Show less

Analyst Consensus ?

ConsensusHold36 ratings
Bullish1438.9%
Neutral1747.2%
Bearish513.9%

Analyst 52W Price Targets

$293.87Current
$151Low
$255.77Average
$337High

Latest persisted target per named analyst; persisted current price from FN2's market snapshot as of Oct 17, 2026. Not an FN2 forecast.

Firm-level rating actions

FMP grade actions identify the grading firm, not a named analyst.

FirmRatingPrior ratingActionDate
Wells Fargo Overweight OverweightMaintainOct 14, 2026
Morgan Stanley Overweight OverweightMaintainOct 9, 2026
Barclays Equal Weight Equal WeightMaintainOct 7, 2026
UBS Neutral NeutralMaintainOct 5, 2026
TD Cowen Buy BuyMaintainOct 5, 2026
Show 31 more rating actions

Named analyst price targets

Upside is calculated against the persisted current price $293.87. FMP does not supply a rating on these named-analyst rows.

FirmAnalyst52W targetPrice when postedUpsideDate
Wells FargoDaniel Welden$315$278.03 +7.2%Oct 14, 2026
Morgan StanleyAnalyst unavailable$337$276.44 +14.7%Oct 9, 2026
BarclaysAnalyst unavailable$281$270.18 -4.4%Oct 7, 2026
UBSAlex Kramm$270$263.14 -8.1%Oct 5, 2026
Wells FargoDaniel Welden$301$265.1 +2.4%Oct 1, 2026
See 67 more

Track every rating change on CME the moment it posts. Free to start.

Start free

Company context

Snapshot as of publication

CME Group Inc., through its various subsidiaries, manages international marketplaces for the exchange of futures and options on futures contracts worldwide. Its extensive array of product offerings includes futures and options linked to a broad spectrum of underlying assets, such as interest rates, equity indices, foreign exchange, agricultural commodities, energy, and metals, alongside fixed-income products.…

Historical context

All CME earnings

Financial Services peers this season

Latest reports in the same sector

Latest beats and misses

Who reports next

Get the CME recap when the next report posts

One email per quarter with the scorecard, the market reaction and what changed on the call. No account needed.

Sources

  1. Earnings call transcript and parsed analysis · 2026-05-11T10:29:34.698584+00:00
  2. FN2 earnings calendar · 2025-01-29T00:04:08.037886+00:00
  3. Polygon adjusted daily market bars · 2026-10-17T10:20:43.376310+00:00
  4. Financial Modeling Prep analyst price-target consensus and quote snapshot · 2026-10-17T10:20:43.373546+00:00

Methodology

Reported and consensus figures come from FN2's earnings event records. Market reaction and volume are calculated from daily adjusted bars around the event; abnormal move subtracts the SPY move over the same window.

Analyst target low, average, and high values are derived at request time from each named analyst's latest persisted FMP target. The current-price marker comes from FN2's persisted market snapshot. They are sell-side estimates, not an FN2 valuation or recommendation.

Transcript intelligence is a structured synthesis of the current and prior earnings-call analyses. Missing values stay missing and are never estimated.

By FN2 Research · Updated · As of 2026-10-17. For educational purposes only; not investment advice.